Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.51 |
| ▸ | MMP8 | P22894 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16103221 | 1.00 | SLC1A1 (0.51) | SLC1A1MMP8EGFRSRCKMT2A | |
| SCHEMBL13151621 | 0.92 | MMP2 (0.52) | SLC1A1MMP8EGFRSRCKMT2A | |
| SCHEMBL16103702 | 0.92 | MMP2 (0.52) | SLC1A1MMP8EGFRSRCKMT2A | |
| SCHEMBL29313122 | 0.88 | SLC1A1 (0.66) | SLC1A1MMP8KMT2AGAAMMP2 | |
| SCHEMBL5788086 | 0.86 | KMT2A (0.55) | SLC1A1MMP8KMT2AMEN1 | |
| SCHEMBL16103393 | 0.85 | MAPT (0.54) | GAASPHK1 | |
| SCHEMBL13151584 | 0.85 | MAPT (0.54) | GAASPHK1 | |
| SCHEMBL7524502 | 0.84 | ALDH1A1 (0.55) | SLC1A1MMP8EGFRSRCKMT2A | |
| SCHEMBL30120748 | 0.84 | MMP2 (0.56) | SLC1A1MMP8EGFRSRCKMT2A | |
| SCHEMBL5555507 | 0.84 | SLC1A1 (0.57) | SLC1A1MMP8EGFRSRCKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-02-09 | — | — | US | disclosed |
| WO-2010118309-A2 | INHIBITORS OF STAT3 AND USES THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035114-A1 | INHIBITORS OF STAT3 AND USES THEREOF | STAT3, JAK2, STAT6 | SLC1A1 3980/4885MMP8 1199/4885EGFR 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.